Engineered T cells for cancer treatment.
Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and The Methodist Hospital, Houston, Texas, USA.
Usanarat
U
Anurathapan
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and The Methodist Hospital, Houston, Texas, USA.
Ann M
AM
Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and The Methodist Hospital, Houston, Texas, USA.
Malcolm K
MK
Brenner
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and The Methodist Hospital, Houston, Texas, USA. Electronic address: jfvera@txch.org.
Juan F
JF
Vera
D000951:Antigens, Neoplasm / Q000096:biosynthesis; D060846:Cell Engineering; D064987:Cell- and Tissue-Based Therapy; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000235:genetics* / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*
D000951:Antigens, Neoplasm; D011993:Recombinant Fusion Proteins
CAR T cells; cancer treatment; genetic modification of T cells; immunotherapy